Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $32

Benzinga · 20h ago
Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $35 to $32.